The following is a summary of the Evogene Ltd. (EVGN) Q4 2024 Earnings Call Transcript:

Financial Performance:

• Evogene reported annual revenues of approximately $8.5 million for 2024, up from $5.6 million in 2023.

• Q4 revenues for 2024 totaled $1.6 million, a substantial increase from $0.6 million in the corresponding quarter in 2023.

• Total R&D expenses for the year were down to $16.6 million, from $20.8 million in 2023, reflecting a reduction in activity following the cessation of Canonic's operations and decreased development expenses in other subsidiaries.

• General and Administrative expenses for 2024 were $7.4 million, increasing from $6.1 million in 2023 mainly due to one-time fundraising-related costs.

• The company narrowed its net loss to $18.1 million for 2024 from $26 million in 2023, driven by increased revenues and reduced R&D expenses.

Business Progress:

• Evogene emphasized the expansion of Casterra's operations with a new delivery schedule and growth into new markets like Brazil and Africa.

• Strategic collaborations and technological advancements were advanced across subsidiaries, including a new collaboration with Bayer for AgPlenus, and progress in Lavie Bio and Biomica's development programs.

• A specific highlight was Evogene's collaboration with Google Cloud to develop a foundational AI model for small molecules drug discovery.

Opportunities:

• Evogene plans to escalate its deployment of the AI-driven tech engines to boost drug discovery and accelerate product development in collaboration with mid-size biotech firms and academic institutions.

• Noteworthy opportunities perceived in the continuous supply chain integration in Casterra and potential market expansions into Brazil and Africa.

Risks:

• Potential operational risks and low revenue intake from new markets could affect overall business progress, especially with new ventures and expansions.

More details: Evogene IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.